Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study to Evaluate ALN-2232 in Participants With Obesity

Eli Lilly · Phase 1/2 · Recruiting · Enrollment 156

NCT07463846

ArmPopulationDoseWeeksEstimandWeight change
Part A: ALN-2232Obesity or overweightn/rn/rn/rn/r
Part A: PlaceboObesity or overweightn/rn/rn/rn/r
Part B: ALN-2232Obesity or overweightn/rn/rn/rn/r
Part B: PlaceboObesity or overweightn/rn/rn/rn/r
Part C: ALN-2232Obesity or overweightn/rn/rn/rn/r
Part C: PlaceboObesity or overweightn/rn/rn/rn/r
Part C: TirzepatideObesity or overweightn/rn/rn/rn/r